Accéder au contenu
Merck
Toutes les photos(1)

Documents

1285873

USP

Fluticasone propionate

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

(6α,11β,16α,17α)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid S-(fluoromethyl) ester

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C25H31F3O5S
Numéro CAS:
80474-14-2
Poids moléculaire :
500.57
Numéro MDL:
MFCD00866007
Code UNSPSC :
41116107
ID de substance PubChem :
329749903
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

fluticasone

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF

InChI

1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1

Clé InChI

WMWTYOKRWGGJOA-CENSZEJFSA-N

Informations sur le gène

human ... NR3C1(2908)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluticasone propionate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Fluticasone Propionate and Salmeterol Inhalation Aerosol®
  • Fluticasone Propionate and Salmeterol Inhalation Powder
  • Fluticasone Propionate Cream
  • Fluticasone Propionate Inhalation Aerosol®
  • Fluticasone Propionate Inhalation Powder
  • Fluticasone Propionate Lotion

Actions biochimiques/physiologiques

Fluticasone propionate is a second generation glucocorticoid. Used as an anti-inflammatory agent for asthma. Shown to enhance eosinophil apoptosis in a concentration-dependent manner via the glucocorticoid receptor.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Informations légales

Aerosol is a registered trademark of Cytec Technology Corp.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0000284

Fluticasone propionate, European Pharmacopoeia (EP) Reference Standard

Y0000221

Fluticasone impurity D, European Pharmacopoeia (EP) Reference Standard

1285884

Fluticasone Propionate Resolution Mixture, United States Pharmacopeia (USP) Reference Standard

1285895

Fluticasone Propionate System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

1285840

Fluticasone Propionate Related Compounds Mixture, United States Pharmacopeia (USP) Reference Standard

1285910

Fluticasone Propionate Nasal Spray Resolution Mixture, United States Pharmacopeia (USP) Reference Standard

Y0001754

Fluticasone propionate for impurity C identification, European Pharmacopoeia (EP) Reference Standard

1285829

Fluticasone propionate Related Compound D, United States Pharmacopeia (USP) Reference Standard

1285818

Fluticasone propionate Related Compound J, United States Pharmacopeia (USP) Reference Standard

PHR1702

Fluticasone Propionate, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1844

Fluticasone Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1842

Fluticasone Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1846

Fluticasone Related Compound J, Pharmaceutical Secondary Standard; Certified Reference Material

BP587

Fluticasone propionate, British Pharmacopoeia (BP) Reference Standard

BP588

Fluticasone S-methyl impurity, British Pharmacopoeia (BP) Reference Standard

Y0002249

Fluticasone propionate for system suitability, CRS, European Pharmacopoeia (EP) Reference Standard

PHR2270

Fluticasone Propionate Impurity A, certified reference material, pharmaceutical secondary standard

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Warning

Mentions de danger

H361f,H373

Classification des risques

Repr. 2 - STOT RE 2

Organes cibles

Endocrine system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 3

1 of 3

vibrant-m

Y0000221

Fluticasone impurity D

USP

USP

1286107

Formoterol fumarate

Mucin from bovine submaxillary glands Type I-S

Sigma-Aldrich

M3895

Mucin from bovine submaxillary glands

M Berger et al.
Allergy, 70(3), 257-264 (2014-11-11)
House dust contains mite allergens as well as bacterial products such as lipopolysaccharide (LPS). Asthma exacerbations are associated with the level of exposure to allergens and LPS. LPS can potentiate allergen effects in steroid-naïve patients. Long-acting β2-agonists (LABA) were shown
Wei Liu et al.
Experimental and therapeutic medicine, 8(4), 1313-1317 (2014-09-05)
This study was designed to determine the expression of serum and sputum surfactant protein D (SP-D) in chronic obstructive pulmonary disease (COPD) and its association with treatment response. Sixty-five treatment-naive patients with COPD and 26 normal control subjects were recruited
T Welte et al.
International journal of clinical practice, 69(3), 336-349 (2014-11-05)
Chronic obstructive pulmonary disease (COPD) is usually a progressive condition. Undiagnosed early-stage disease, particularly in symptomatic patients, is likely to become more severe with time. Hence, prevention or reduction in disease progression is highly relevant. We evaluated the published data
Brian L Le et al.
Research square (2021-04-07)
The novel SARS-CoV-2 virus emerged in December 2019 and has few effective treatments. We applied a computational drug repositioning pipeline to SARS-CoV-2 differential gene expression signatures derived from publicly available data. We utilized three independent published studies to acquire or
Juliet M Foster et al.
The Journal of allergy and clinical immunology, 134(6), 1260-1268 (2014-07-27)
Poor adherence contributes to uncontrolled asthma. Pragmatic adherence interventions for primary care settings are lacking. To test the effectiveness of 2 brief general practitioner (GP)-delivered interventions for improving adherence and asthma control. In a 6-month cluster randomized 2 × 2
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique